Mixed Pain (Nociceptive and Neuropathic)

2

Review clinical trials related to Mixed Pain (Nociceptive and Neuropathic). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

S1R Imaging-Based Cryoneurolysis in Chronic Pain

The goal of this clinical trial is to determine whether a sigma-1 receptor PET/MRI scan can help identify the specific nerves responsible for chronic pain. Researchers will use an investigational imaging agent called \[18F\]FTC-146 to look for signs of pain generating nerve irritation or injury that may not be visible on convention imaging tests. Participants whose pain-generating nerve can be identified may undergo a diagnostic nerve block and, if successful, a standard clinical procedure called cryoneurolysis will be used to temporarily interrupt pain signals.

Participants needed: 6
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Davidzon, Guido, M.D.Updated: Aug 17, 2026
Eligibility criteria

Chronic nociceptive, neuropathic, or mixed pain for ≥2 months [+5]

Pregnancy or nursing. [+4]

Status: Not yet recruiting

PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin

The purpose of this study is to compare the uptake of \[18F\]FTC-146 in healthy volunteers to that of individuals suffering from chronic pain with Spinal or Peripheral Nerve Origin. Primary Objectives: A) To quantify the bio-distribution of \[18F\] FTC-146 uptake in subjects with Spinal or Peripheral Nerve Origin pain and compare it with healthy controls. B) To determine whether painful schwannomas can be differentiated from non-painful schwannomas based on imaging. Secondary Objectives: A) To assess the reproducibility of \[18F\]FTC-146 PET imaging within the same healthy volunteer subjects using Test-Retest analysis. B) To investigate whether post-treatment \[18F\]FTC-146 uptake differs from pre-treatment uptake and correlate the imaging with subject reported pain level after treatment

Participants needed: 200
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Stanford UniversityUpdated: Sep 19, 2024
Eligibility criteria

Healthy Volunteers [+5]

Healthy Volunteers [+13]